Fusarium species,Scedosporium species, and Lomentospora prolificans: A systematic review to inform the World Health Organization priority list of fungal pathogens.

Autor:	Marinelli T; Department of Infectious Diseases and Microbiology, Royal Prince Alfred Hospital, Sydney, Australia., Kim HY; Sydney Infectious Diseases Institute (Sydney ID), The University of Sydney, New South Wales, Australia.; Faculty of Medicine and Health, School of Pharmacy, The University of Sydney, New South Wales, Australia.; Department of Pharmacy, Westmead Hospital, Westmead, New South Wales, Australia., Halliday CL; Centre for Infectious Diseases and Microbiology Laboratory Services, Institute of Clinical Pathology and Medical Research, New South Wales Health Pathology, Westmead Hospital, Westmead, New South Wales, Australia., Garnham K; Department of Infectious Diseases and Microbiology, Gold Coast University Hospital, Southport, Queensland, Australia., Bupha-Intr O; Department of Infection Services, Wellington Regional Hospital, Wellington, New Zealand., Dao A; Sydney Infectious Diseases Institute (Sydney ID), The University of Sydney, New South Wales, Australia.; Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Camperdown, Australia.; Children's Hospital at Westmead, Westmead, New South Wales, Australia., Morris AJ; Department of Clinical Microbiology, Auckland City Hospital, Grafton, Auckland, New Zealand., Alastruey-Izquierdo A; Mycology Reference Laboratory, National Centre for Microbiology, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain., Colombo A; Departamento de Medicina, Division of Infectious Diseases, Hospital São Paulo, Escola Paulista de Medicina (EPM), Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil., Rickerts V; Robert Koch Institute Berlin, Berlin, Germany., Perfect J; Division of Infectious Diseases and International Health, Duke University School of Medicine, Durham, North Carolina, USA., Denning DW; Manchester Fungal Infection Group, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK., Nucci M; Universidade Federal do Rio de Janeiro and Grupo Oncoclinicas, Rio de Janeiro, Brazil., Hamers RL; Oxford University Clinical Research Unit Indonesia, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia.; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Cassini A; Infectious Diseases Service, Lausanne University Hospital, Lausanne, Switzerland.; Public Health Department, Lausanne, Switzerland., Oladele R; Department of Medical Microbiology and Parasitology, College of Medicine, University of Lagos, Lagos, Nigeria., Sorrell TC; Sydney Infectious Diseases Institute (Sydney ID), The University of Sydney, New South Wales, Australia.; Department of Pharmacy, Westmead Hospital, Westmead, New South Wales, Australia., Ramon-Pardo P; Department of Communicable Diseases Prevention, Control and Elimination, Pan American Health Organization, Washington, District of Columbia, USA., Fusire T; South East Asia Region Office, World Health Organization, New Delhi, India., Chiller TM; Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Wahyuningsih R; Department of Parasitology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.; Department of Parasitology, Faculty of Medicine, Universitas Kristen, Jakarta, Indonesia., Forastiero A; Department of Communicable Diseases Prevention, Control and Elimination, Pan American Health Organization, Washington, District of Columbia, USA., Al-Nuseirat A; Department of Health Systems, World Health Organization, Regional Office of the Eastern Mediterranean, Cairo, Egypt., Beyer P; Global Antibiotics Research and Development Partnership, Drugs for Neglected Diseases Initiative, Geneva, Switzerland., Gigante V; AMR Division, World Health Organization, Geneva, Switzerland., Beardsley J; Sydney Infectious Diseases Institute (Sydney ID), The University of Sydney, New South Wales, Australia.; Westmead Institute for Medical Research, Westmead, New South Wales, Australia., Sati H; AMR Division, World Health Organization, Geneva, Switzerland., Alffenaar JW; Sydney Infectious Diseases Institute (Sydney ID), The University of Sydney, New South Wales, Australia.; Faculty of Medicine and Health, School of Pharmacy, The University of Sydney, New South Wales, Australia.; Department of Pharmacy, Westmead Hospital, Westmead, New South Wales, Australia., Morrissey CO; Department of Infectious Diseases, Alfred Health and Monash University, Melbourne, Victoria, Australia.
Jazyk:	angličtina
Zdroj:	Medical mycology [Med Mycol] 2024 Jun 27; Vol. 62 (6).
DOI:	10.1093/mmy/myad128
Abstrakt:	Recognizing the growing global burden of fungal infections, the World Health Organization established a process to develop a priority list of fungal pathogens (FPPL). In this systematic review, we aimed to evaluate the epidemiology and impact of infections caused by Fusarium spp., Scedosporium spp., and Lomentospora prolificans to inform the first FPPL. PubMed and Web of Sciences databases were searched to identify studies published between January 1, 2011 and February 23, 2021, reporting on mortality, complications and sequelae, antifungal susceptibility, preventability, annual incidence, and trends. Overall, 20, 11, and 9 articles were included for Fusarium spp., Scedosporium spp., and L. prolificans, respectively. Mortality rates were high in those with invasive fusariosis, scedosporiosis, and lomentosporiosis (42.9%-66.7%, 42.4%-46.9%, and 50.0%-71.4%, respectively). Antifungal susceptibility data, based on small isolate numbers, showed high minimum inhibitory concentrations (MIC)/minimum effective concentrations for most currently available antifungal agents. The median/mode MIC for itraconazole and isavuconazole were ≥16 mg/l for all three pathogens. Based on limited data, these fungi are emerging. Invasive fusariosis increased from 0.08 cases/100 000 admissions to 0.22 cases/100 000 admissions over the time periods of 2000-2009 and 2010-2015, respectively, and in lung transplant recipients, Scedosporium spp. and L. prolificans were only detected from 2014 onwards. Global surveillance to better delineate antifungal susceptibility, risk factors, sequelae, and outcomes is required. (© The Author(s) 2023. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu